# A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

> **NCT02596100** · PHASE1 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Betrixaban

## Key facts

- **NCT ID:** NCT02596100
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596100, "A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02596100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*